Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. - Wikidata - awgldk - TriplyDB

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

http://www.wikidata.org/entity/Q53142391

about

Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod Imaging plaques to predict and better manage patients with acute coronary events p38 MAPK in cardioprotection - are we there yet?The case for inhibiting p38 mitogen-activated protein kinase in heart failure Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis P38α MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism.Detection of vulnerable atherosclerotic plaque and prediction of thrombosis events in a rabbit model using 18F-FDG -PET/CT Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with Arginase-II and S6K1 signaling pathway Aortic ¹⁸F-FDG uptake in patients suffering from granulomatosis with polyangiitis.Arginase: the emerging therapeutic target for vascular oxidative stress and inflammation.Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.Imaging atherosclerosis and risk of plaque rupture Thresholds for Arterial Wall Inflammation Quantified by (18)F-FDG PET Imaging: Implications for Vascular Interventional Studies Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.The advancing clinical impact of molecular imaging in CVD.Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses.Lipid lowering and imaging protease activation in atherosclerosis.Positron emission tomography of the vulnerable atherosclerotic plaque in man--a contemporary review Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.PET imaging of inflammation in atherosclerosis.Recent advances in visualizing vulnerable plaque: focus on noninvasive molecular imaging.PET imaging of atherosclerosis.Pericoronary adipose tissue: a novel therapeutic target in obesity-related coronary atherosclerosis.Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification.Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation.Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis.N-Caffeoyltryptamine, a Potent Anti-Inflammatory Phenolic Amide, Suppressed MCP-1 Expression in LPS-stimulated THP-1 Cells and Rats Fed a High-Fat Diet.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Inflammatory processes in cardiovascular disease: a route to targeted therapies.The future of imaging in cardiovascular disease intervention trials: 2017 and beyond.Imaging atherosclerosis with positron emission tomography.Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression.LATITUDE-TIMI: is there still hope for anti-inflammatory therapy in acute myocardial infaction?Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod.Losmapimod does not reduce cardiovascular events in patients with acute myocardial infarction.Feasibility of simultaneous PET/MR in diet-induced atherosclerotic minipig: a pilot study for translational imaging.Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.PET/CT evaluation of 18F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions' formation?Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomogra

P2860

Q26798359-89D11890-6709-403B-AD3A-960F99AE13F5 Q26999943-00100DE6-11E2-4BBA-A70A-BF36EE27A173 Q27001653-4D418925-E1B5-4194-AAB0-FB289BDF85D4 Q28080674-DA9E105B-B6ED-4E71-82AC-9848B0E73B3C Q33624371-97D9A85E-2CFE-42DB-B00F-D0BFEC58661E Q33838927-B81E2D12-FCD5-4355-B97A-8F3117B7EC84 Q34285775-E58C39C6-F4A9-4348-976E-511ED3859C50 Q34684088-DA186162-7937-4F48-AFF0-16EE8441DE28 Q35149545-4A9B3A34-F98C-4D3A-B576-3943DDF0E555 Q35851713-F0ED6E7D-830E-45C5-AE4A-70245E0F178C Q36920831-30F40135-C678-424D-83B5-185666D871BC Q36988007-81AFA10D-B377-43D6-9439-2D22C0752D5A Q37275443-39AE3D0B-904B-4AE7-9BE5-D1E797BD1E8E Q37324445-B4E6F4D8-144B-4CBB-8446-08AD670B3CE1 Q37338935-1AFA9252-7C1F-4F51-8A15-B16F456290B8 Q37423120-38B3A61D-96D9-4483-BD3D-4878A2D9D758 Q37688086-A6807C28-1595-44FD-A67E-8A2F551E88B6 Q37710107-175EDC90-816C-4623-9768-D2F7C2B0FC71 Q38167348-ABB88A97-B4AC-4229-AF01-ECEBF6D3AA31 Q38185979-C6375870-036B-44EE-B0BE-6D1109AF5E95 Q38218902-AC38AB91-7745-498D-99E0-422675CEC2DE Q38233595-C3F95D4F-88BF-4111-80DF-78D203A6B00A Q38326673-ABA038D5-9EC9-4FDD-B7E3-D1695B31F432 Q38373558-45E04F50-2B88-4E56-95A3-DACABF830094 Q38397910-D29E7B08-6153-4BE2-97F4-8BC3B768F7B1 Q38412151-D659F781-087D-47EF-9346-ADF6FE936258 Q38605303-570262EE-229F-4B34-956F-C499E72A0A69 Q38758037-E5E91E4A-8E1A-47F9-B2E5-0D54F65C8C1E Q38786058-7B66F2EB-A3C1-4588-BBB4-D9E1BAEECE82 Q38788685-AA04212B-570D-496A-88FA-B75243238AF9 Q38800754-61BD7831-0FCB-49A0-BF01-DFB83941E843 Q38820272-C6FDFFFD-127B-414C-8FA8-33EF009E205A Q39293450-B7245361-14FC-4F9C-A424-EB0D6796A57E Q41428927-F6C49A8C-1B6F-4A18-AC92-7FF6EBDE706B Q41543188-B91013D6-1D53-4C61-841E-26FCF2A0D09E Q42384664-EF8C946D-D581-4C8D-ABA0-C136B3719BB8 Q42814382-585BF844-B73E-405D-9AA1-571870FC19FF Q44613025-3A651133-A0FA-42DE-B798-86948550E99C Q50697336-FAA92229-6861-4381-BA7D-0CEA02BF22C2 Q50957944-51E9AAD7-DFFE-4008-B87F-C9414B0317AC

P2860

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

http://www.wikidata.org/entity/Q53142391

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@en

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@nl

type

label

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@en

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@nl

prefLabel

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@en

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@nl

P1433

Q53142391-80F90014-10C9-4847-9A8C-D25DE810A493

P1476

Q53142391-63FEACCE-AC75-4651-8C06-B752EA8DD6AB

P2093

Q53142391-050430E3-B670-4F85-B20C-1FFBBBE0A8FF

Q53142391-1BEBF9DB-33E9-4C7F-BAD7-B9506FBBB620

Q53142391-302A9BBB-1C36-45B2-8179-D9D76D01896C

Q53142391-343A8C38-7857-4F9C-B736-DA807BA6F265

Q53142391-594883CB-B324-4DDA-95E4-20D62164A687

Q53142391-5C346D7E-1D50-485D-A909-A01D14013344

Q53142391-6BC164AE-264C-4976-AF28-1F548557D786

Q53142391-95EB1AE3-2C0C-4F7F-B9B3-54592A70534E

Q53142391-98BA2840-0C91-4A29-98C1-568B5F5EBF96

Q53142391-C1134DD8-4DF3-40B2-B5F5-A440E4CAEB56

P304

Q53142391-99E4D01C-5524-41D9-AB3E-24301ABC9693

P31

Q53142391-9E88E61B-686C-4D65-B640-F03492D6BBDF

P356

Q53142391-59713023-60E4-4816-864A-8C69F771E23F

P433

Q53142391-FDCCF164-BA09-4785-9A04-3CC2DED46859

P478

Q53142391-35A8940A-B828-4590-B69D-329B452F6864

P50

Q53142391-85AD705B-AF14-4A36-8980-157B3F108273

Q53142391-B1EC0C8A-E9A6-47D4-AB3A-1FD2F4737703

P577

Q53142391-F74CCC18-D0AB-4D7E-8307-9BCA68A002F9

P5875

Q53142391-E136784B-6DAA-45D2-9858-206BD6BE7B9C

P698

Q53142391-4C10FC40-E109-4BA8-9CC9-17BD8772395E

P921

Q53142391-54561C77-CA54-45B0-BCCD-28DD66D0BB2F

Q53142391-648E9CD8-97EB-4B71-ADC5-AC7875A4CF3E

P356

J.JCMG.2012.02.016

P1433

JACC: Cardiovascular Imaging

P1476

Effects of p38 mitogen-activat ...... patients with atherosclerosis.

@en

P2093

Ahmed Tawakol

http://www.w3.org/2001/XMLSchema#string

Bill Davis

http://www.w3.org/2001/XMLSchema#string

David J Collier

http://www.w3.org/2001/XMLSchema#string

Dennis L Sprecher

http://www.w3.org/2001/XMLSchema#string

Fergus V Gleeson

http://www.w3.org/2001/XMLSchema#string

Gengqian Cai

http://www.w3.org/2001/XMLSchema#string

Ian B Wilkinson

http://www.w3.org/2001/XMLSchema#string

James H F Rudd

http://www.w3.org/2001/XMLSchema#string

John J Lepore

http://www.w3.org/2001/XMLSchema#string

L Ceri Davies

http://www.w3.org/2001/XMLSchema#string

P304

911-922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCMG.2012.02.016

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Joseph Cheriyan

Michael S. Marber

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230848221

http://www.w3.org/2001/XMLSchema#string

P698

22974804

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis